Emergent BioSolutions Announces Management Promotions
Emergent BioSolutions Inc. (NYSE: EBS) announced today the promotion of a number of key executives to positions of expanded responsibility to support the company's global business development...
CORRECTING and REPLACING Emergent BioSolutions Reports Financial Results for 2006
In BW5440 issued March 22, 2007: Third graph, first sentence should read: "2006 was a record year for Emergent BioSolutions in terms of our total revenues and represented our fifth consecutive year...
Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the company's Anthrax...
Emergent BioSolutions to Host Conference Call on March 22, 2007 to Announce Fourth Quarter and Full Year 2006 Financial Results
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will report financial results for the fourth quarter and full year 2006 on Thursday, March 22, 2007, before market...
Emergent BioSolutions to Present at the Cowen & Company 27th Annual Health Care Conference
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will present at the Cowen and Company 27th Annual Health Care Conference in Boston. Fuad El-Hibri, chairman and chief executive officer...
Emergent BioSolutions Delivers Approximately 1 Million Doses of BioThrax(R) Ahead of Schedule to U.S. Department of Health and Human Services for Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE: EBS) announced that yesterday it delivered just under one million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), the only FDA licensed anthrax vaccine, to the...
Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has been informed by the National Institute of Allergy and Infectious Diseases (NIAID) that NIAID has cancelled its solicitation for...
FDA Grants Fast Track Designation to Emergent BioSolutions’ BioThrax(R) for Post-Exposure Prophylaxis against Anthrax Infection
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BioThrax(R) (Anthrax Vaccine Adsorbed) as a...
Emergent BioSolutions to Present at BIO CEO & Investor Conference
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it will present at the BIO CEO & Investor Conference 2007 in New York. Fuad El-Hibri, president, chief executive officer and chairman of the...
Emergent BioSolutions Announces Expected 2006 Total Revenue of Approximately $150 Million
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its total revenues for 2006 are estimated to be approximately $150 million, based on the company's preliminary, unaudited results for full...
National Institutes of Health to Sponsor Clinical Trial for Emergent BioSolutions’ Group B Streptococcus Vaccine Candidate
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed a clinical trial agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National...
Emergent BioSolutions Applauds Passage and Signing of BARDA Legislation
Emergent BioSolutions Inc. (NYSE:EBS), a leader in biodefense medical countermeasures, today applauded Congress and President Bush as he signed into law the Pandemic and All-Hazards Preparedness Act,...